Adalimumab therapy for childhood uveitis.

  title={Adalimumab therapy for childhood uveitis.},
  author={Liza B Vazquez-Cobian and Thomas Flynn and Thomas J. A. Lehman},
  journal={The Journal of pediatrics},
  volume={149 4},
Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.